We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+32.61%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$439M
AUM Growth
+$21.9M
Cap. Flow
-$50M
Cap. Flow %
-11.37%
Top 10 Hldgs %
49.48%
Holding
86
New
10
Increased
12
Reduced
30
Closed
14

Top Buys

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$4.87M
2
PODD icon
Insulet
PODD
+$2.97M
3
KALV
KalVista Pharmaceuticals
KALV
+$2.75M
4
CATX icon
Perspective Therapeutics
CATX
+$2.65M
5
LRMR icon
Larimar Therapeutics
LRMR
+$2.59M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15.2M
2
IMGN
Immunogen Inc
IMGN
+$5.74M
3
SAGE
Sage Therapeutics
SAGE
+$5.31M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$5.25M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.43%
2 Miscellaneous 13.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$40.9M 9.31%
431,215
-52,785
-11% -$4.9M
STXS icon
2
Stereotaxis
STXS
$145M
$35.7M 8.13%
13,680,554
– –
CYTK icon
3
Cytokinetics
CYTK
$10B
$27.9M 6.35%
398,100
-1,900
-0.5% -$147K
IDYA icon
4
IDEAYA Biosciences
IDYA
$3.87B
$19.6M 4.46%
446,341
-70,000
-14% -$3.01M
MRUS
5
DELISTED
Merus
MRUS
$17.1M 3.89%
378,995
-75,875
-17% -$3.08M
RVMD icon
6
Revolution Medicines
RVMD
$44.6B
$16.5M 3.76%
511,894
– –
VKTX icon
7
Viking Therapeutics
VKTX
$3.75B
$15.9M 3.62%
194,117
-54,100
-22% -$2.41M
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.74B
$15.7M 3.57%
659,574
-83,000
-11% -$1.85M
IBB icon
9
iShares Biotechnology ETF
IBB
$10.5B
$14.1M 3.2%
102,500
– –
ASND icon
10
Ascendis Pharma A/S
ASND
$16.3B
$14M 3.18%
92,472
-31,000
-25% -$4.42M
XENE icon
11
Xenon Pharmaceuticals
XENE
$5.81B
$11.8M 2.68%
273,739
-3,000
-1% -$138K
DAWN
12
DELISTED
Day One Biopharmaceuticals
DAWN
$11M 2.51%
666,463
-20,000
-3% -$299K
BPMC
13
DELISTED
Blueprint Medicines
BPMC
$10.1M 2.31%
106,763
-4,100
-4% -$352K
NBIX icon
14
Neurocrine Biosciences
NBIX
$15.7B
$9.88M 2.25%
71,615
-1,000
-1% -$137K
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$9.57M 2.18%
806,973
+205,941
+34% +$2.75M
TNDM icon
16
Tandem Diabetes Care
TNDM
$1.49B
$9.14M 2.08%
258,208
+37,500
+17% +$1M
DXCM icon
17
DexCom
DXCM
$34.3B
$9.09M 2.07%
65,552
-2,000
-3% -$251K
KURA icon
18
Kura Oncology
KURA
$1.13B
$8.8M 2%
412,663
-80,021
-16% -$1.56M
ATRC icon
19
AtriCure
ATRC
$2.47B
$8.24M 1.88%
271,029
+145,500
+116% +$4.87M
MORF
20
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$8.16M 1.86%
231,748
– –
AXGN icon
21
Axogen
AXGN
$2.77B
$7.55M 1.72%
935,894
– –
BHVN icon
22
Biohaven
BHVN
$2.33B
$6.49M 1.48%
118,730
-50,042
-30% -$2.48M
TSVT
23
DELISTED
2seventy bio
TSVT
$6.44M 1.47%
1,204,051
-243,414
-17% -$1.14M
EWTX icon
24
Edgewise Therapeutics
EWTX
$4.64B
$5.59M 1.27%
306,197
-143,187
-32% -$2.28M
ALEC icon
25
Alector
ALEC
$261M
$5.5M 1.25%
912,928
+303,023
+50% +$1.98M
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, DAFNA Capital Management held 86 positions worth $439M, up 5.3% from $417M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management withdrew a net $50M in Q1 2024, closing 14 positions and reducing 30 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in Insulet worth $2.73M.

  • DAFNA Capital Management's largest Q1 2024 buy was Insulet: 15,900 shares worth $2.73M.
  • DAFNA Capital Management added most to AtriCure in Q1 2024, an estimated $4.87M increase.
  • DAFNA Capital Management's biggest Q1 2024 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.9M.
  • DAFNA Capital Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $15.2M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $439M portfolio in Q1 2024.
  • DAFNA Capital Management opened 10 new positions and closed 14 in Q1 2024.
  • DAFNA Capital Management's portfolio value rose 5.3% quarter-over-quarter to $439M.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.